Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

Summary

This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients are counseled on post-operative pain management and then may opt into or out of the study with randomization to discharge prescriptions including (A) multimodal plan with additional automatic opioid prescription or (B) multimodal plan alone and instruction to call phone line to request opioid prescription if pain management is insufficient.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Opioid Consumption, Postoperative
• Multimodal Analgesia
• Robotic Assisted Laparoscopic Surgery
• Robotic Assisted Laparoscopic Radical Prostatectomy
• Prostate Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

45 years and older

Sex

Male

Healthy volunteers

Not accepted

Sponsor

Brigham and Women's Hospital

Last updated on ClinicalTrials.gov

May 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites